Results 1 to 10 of about 33,352 (334)

Ibrutinib as initial therapy for patients with chronic lymphocytic leukemia [PDF]

New England Journal of Medicine, 2015
Background: chronic lymphocytic leukemia (CLL) primarily affects older persons who often have coexisting conditions in addition to disease-related immunosuppression and myelosuppression. We conducted an international, open-label, randomized phase 3 trial
ABRISQUETA, Pau, ARSLAND, Onder, ATANASIO, Carolina Moreno, ATKINS, James, BADOUX, Xavier, Bairey, O., Barr, P. M., BARRIENTOS, Jaqueline, BARTLETT, N. L., BRAESTER, Andrei, BRON, Dominique, BURGER, J. A., CAMPBELL, Philip, CHENG, M., CLOW, F., CORBETT, Gillian, CORTELEZZI, Agostino, COUGHLIN, Paul, COUTRE, S., DE OTEYZA, Jaime Perez, DELGADO, Julio, Demirkan, Fatih, DEVEREUX, S., DUNCOMBE, Andrew, FEGAN, Christopher, FINEMAN, Riva, FOA, Roberto, FOX, Christopher, GAIDANO, G., GANLY, Peter, GASIC, Slavisa, GHIA, P., GILL, Devinder, GONZALEZ-BARCA, Eva, GROSICKI, S., HAMBLIN, Michael, HARRUP, Rosemary, HAWKINS, Timothy, HELLMANN, A., HILLMEN, P., HOU, Jing-Zhou, JAMES, D. F., JANSSENS, A., JEN, Jie, JINDRA, Pavel, JING, Hongmei, KAPLAN, Polina, KASYCH, Muzhdaba, Kaynar, Leylagül, KEATING, Michael, KINGSLEY, Edwin, KIPPS, T. J., KUSS, Bryone, LARRATT, Loree, LI, J., MARASCA, Roberto, MARCO, Jose Antonio Garcia, MASLYAK, Z., MAYER, J., MCCARTHY, H., O'DWYER, M., OFFNER, F., OLIYNYK, Hanna, OPAT, Stephen, Owen, C., PLUTA, Andrzej, POLLIACK, A., PRISTUPA, Alexander, PYLYPENKO, Halyna, QUACH, H., QUACKENBUSH, Robert, ROBAK, T., RUCHLEMER, Rosa, Schuh, A., SEMENZATO, Gianpietro, SHADMAN, Mazyar, SIDDIQI, T., SIMKOVIC, Martin, SIMPSON, D., STEVENS, D. A., STYLES, L., SURI, D., TADMOR, Tamar, TAM, C. S., TEDESCHI, A., THIRMAN, Michael, TIRUMALI, Nagendra, TURNER, Paul, VAN DEN NESTE, Eric, VANDENBERGHE, Elisabeth, Vural, Filiz, WEINKOVE, Robert, WU, Ka Lung, YAGCI, Munci, ZHU, Jun, ZINZANI, Pier Luigi   +95 more
core   +6 more sources

Ibrutinib inhibits SDF1/CXCR4 mediated migration in AML [PDF]

, 2014
Pharmacological targeting of BTK using ibrutinib has recently shown encouraging clinical activity in a range of lymphoid malignancies. Recently we reported that ibrutinib inhibits human acute myeloid leukemia (AML) blast proliferation and leukemic cell ...
Bowles, Kristian M, Lawes, Matthew J, MacEwan, David J, Murray, Megan Y, Rushworth, Stuart A, Shafat, Manar S., Zaitseva, Lyubov   +6 more
core   +11 more sources

Targeting BTK with Ibrutinib in Relapsed Chronic Lymphocytic Leukemia [PDF]

New England Journal of Medicine, 2013
BACKGROUND The treatment of relapsed chronic lymphocytic leukemia (CLL) has resulted in few durable remissions. Bruton's tyrosine kinase (BTK), an essential component of B-cell-receptor signaling, mediates interactions with the tumor microenvironment and
John C. Byrd, Richard R. Furman, Steven Coutré, Ian W. Flinn, Jan A. Burger, Kristie A. Blum, Barbara Grant, Jeff P. Sharman, Morton Coleman, William G. Wierda, Jeffrey A. Jones, Weiqiang Zhao, Nyla A. Heerema, Amy J. Johnson, Juthamas Sukbuntherng, Betty Chang, Fong Clow, Eric Hedrick, Joseph J. Buggy, Danelle F. James, Susan O’Brien   +20 more
openalex   +2 more sources

Acalabrutinib Versus Ibrutinib in Previously Treated Chronic Lymphocytic Leukemia: Results of the First Randomized Phase III Trial

Journal of Clinical Oncology, 2021
PURPOSE Among Bruton's tyrosine kinase inhibitors, acalabrutinib has greater selectivity than ibrutinib, which we hypothesized would improve continuous therapy tolerability.
Richard R Furman, Neil E Kay, John C Byrd   +2 more
exaly   +2 more sources

Ibrutinib regimens versus chemoimmunotherapy in older patients with untreated CLL [PDF]

New England Journal of Medicine, 2018
BACKGROUND Ibrutinib has been approved by the Food and Drug Administration for the treatment of patients with untreated chronic lymphocytic leukemia (CLL) since 2016 but has not been compared with chemoimmunotherapy.
Bartlett, Nancy L.
core   +3 more sources

Long-term efficacy and safety of first-line ibrutinib treatment for patients with CLL/SLL: 5 years of follow-up from the phase 3 RESONATE-2 study. [PDF]

Leukemia, 2019
RESONATE-2 is a phase 3 study of first-line ibrutinib versus chlorambucil in chronic lymphocytic leukemia (CLL)/small lymphocytic lymphoma (SLL). Patients aged ≥65 years (n = 269) were randomized 1:1 to once-daily ibrutinib 420 mg continuously or ...
Bairey, Osnat, Barr, Paul M., Burger, Jan A., Coutre, Steven E., Dai, Sandra, Dean, James P., Devereux, Stephen, Ghia, P, Grosicki, Sebastian, Hillmen, Peter, Kipps, Thomas J., Lal, Indu, McCarthy, Helen, Moreno, Carol, Offner, Fritz, Owen, Carolyn, Robak, Tadeusz, Simpson, David, Tedeschi, Alessandra, Universitat Autònoma de Barcelona   +19 more
core   +4 more sources

Randomized Phase III Trial of Ibrutinib and Rituximab Plus Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone in Non–Germinal Center B-Cell Diffuse Large B-Cell Lymphoma

Journal of Clinical Oncology, 2019
PURPOSE Ibrutinib has shown activity in non-germinal center B-cell diffuse large B-cell lymphoma (DLBCL). This double-blind phase III study evaluated ibrutinib and rituximab plus cyclophosphamide, doxorubicin, vincristine, and prednisone (R-CHOP) in ...
Anas Younes, Peter W M Johnson, Pier Luigi Zinzani   +2 more
exaly   +2 more sources

Final analysis from RESONATE: Up to six years of follow‐up on ibrutinib in patients with previously treated chronic lymphocytic leukemia or small lymphocytic lymphoma [PDF]

American journal of hematology/oncology, 2019
Ibrutinib, a once‐daily oral inhibitor of Bruton's tyrosine kinase, is approved in the United States and Europe for treatment of patients with chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL).
Barr, P.M., Barrientos, J.C., Brown, J.R., Burger, J.A., Byrd, J.C., Coutre, S., Dai, S., Dean, J.P., Hillmen, Peter, Jaeger, U., Kipps, T.J., Montillo, M., Moreno, Carol, Mulligan, S.P., Munir, T., O'Brien, Susan, Reddy, N.M., Szoke, A., Tam, C.S., Universitat Autònoma de Barcelona, Woyach, J.A.   +20 more
core   +5 more sources

Ibrutinib inhibits platelet integrin αIIbβ3 outside-in signaling and thrombus stability but not adhesion to collagen [PDF]

, 2015
OBJECTIVE: Ibrutinib is an irreversible Bruton tyrosine kinase inhibitor approved for treatment of Waldenstrom macroglobulinemia, chronic lymphocytic leukemia, and mantle cell lymphoma that increases the risk of bleeding among patients. Platelets from
Alexander P. Bye, Alexander R. Stainer, Amanda J. Unsworth, Jonathan M. Gibbins, Michael J. Fry, Oda A, Sakthivel Vaiyapuri   +6 more
core   +3 more sources

Ibrutinib [PDF]

Australian Prescriber, 2015
openaire   +3 more sources